FAKTOR-OPTIONSSCHEIN - GENMAB | Market Closed - Börse Stuttgart 02:20:31 2024-05-31 pm EDT | ||
| 11.66 EUR | -1.10% |
|
| Current month | +6.48% | ||
| 1 month | +6.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 11.66 | -1.10% |
| 24-05-30 | 11.79 | -3.04% |
| 24-05-29 | 12.16 | +5.65% |
| 24-05-28 | 11.51 | +1.77% |
| 24-05-27 | 11.31 | +7.71% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 02:20 pm EDT
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | Morgan Stanley |
| WKN | MG1KCE |
| ISIN | DE000MG1KCE2 |
| Date issued | 2024-04-03 |
| Strike | 2,575 kr |
| Maturity | Unlimited |
| Parity | 7.28 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.83 € |
|---|---|
| Lowest since issue | 9.89 € |
| Spread | 0.27 € |
| Spread % | 2.29% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,937
DKK
Average target price
2,466
DKK
Spread / Average Target
+27.30%
- Stock Market
- Certificates
- Certificat
